Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRA | P10827 | 13/20 | 0.36 |
| ▸ | THRB | P10828 | 13/20 | 0.36 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.34 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.33 |
| ▸ | PPARG | P37231 | 1/20 | 0.33 |
| ▸ | RAF1 | P04049 | 2/20 | 0.33 |
| ▸ | BRAF | P15056 | 2/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3982085 | 0.94 | GRIN1 (0.35) | THRATHRBGRIN1GRIN2B | |
| SCHEMBL3982088 | 0.86 | GRIN1 (0.33) | THRATHRBGRIN1GRIN2BMEN1 | |
| SCHEMBL4302453 | 0.84 | THRA (0.37) | THRATHRBPPARG | |
| SCHEMBL3981701 | 0.81 | THRA (0.39) | THRATHRBPPARG | |
| SCHEMBL3985944 | 0.81 | THRA (0.39) | THRATHRBPPARG | |
| SCHEMBL4297760 | 0.81 | THRB (0.37) | THRATHRBPPARG | |
| SCHEMBL3981706 | 0.81 | THRA (0.39) | THRATHRBPPARG | |
| SCHEMBL3979612 | 0.81 | THRA (0.40) | THRATHRB | |
| SCHEMBL3975144 | 0.80 | THRB (0.37) | THRATHRBPPARG | |
| SCHEMBL3979489 | 0.80 | EGLN1 (0.39) | THRATHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090318514-A1 | Novel Pharmaceutical Compositions | KARO BIO AB (SE) | 2009-12-24 | — | — | US | disclosed |
| US-20090318514-A1 | Novel Pharmaceutical Compositions | KARO BIO AB (SE) | 2009-12-24 | — | — | US | disclosed |
| US-20090318514-A1 | Novel Pharmaceutical Compositions | KARO BIO AB (SE) | 2009-12-24 | — | — | US | disclosed |
| WO-2007128492-A1 | NOVEL PHARMACEUTICAL COMPOSITIONS | KARO BIO AB (SE) | 2007-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318514-A1 | Novel Pharmaceutical Compositions | TSHR, TRHR, THRA | THRA 3/4885THRB 5/4885GRIN1 2827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.